Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).
China Resources Pharmaceutical Group Ltd. is in discussions to form a fund with a projected size of RMB500 million, aimed at investing in high-growth enterprises in synthetic biology, innovative drugs, and biotechnology. The company’s proposed capital commitment is approximately RMB123 million, representing 24.6% of the total fund commitment, with Shenzhen CR Capital expected to manage the fund. The formation of the fund involves a connected transaction due to the involvement of Hanwei Huayou Shantou, a connected person under the company’s controlling shareholder, CRH.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of innovative drugs, synthetic biology, and biotechnology solutions. The company is involved in various pharmaceutical investments and partnerships to enhance its market presence.
Average Trading Volume: 11,021,089
Technical Sentiment Signal: Sell
Current Market Cap: HK$32.54B
For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.